Conjustar Biologics Awarded to PharmCube's "Top 15 Emerging Innovative Drug Enterprises in China – 2025"

Conjustar Biologics (星联肽生物), a clinical-stage biotech company focused on miniaturized conjugate drugs—peptide-drug conjugates (PDCs) and Nanobody-drug conjugates (NDCs)—has been awarded to PharmCube's "Top 15 Emerging Innovative Drug Enterprises in China (2025)"​ at the 2026 OneBD Pharmaceutical Investment & BD Conference, held May 21 in Shanghai.

Presentations in European Society for Medical Oncology (ESMO) Congress 2025

SC-101, a Nectin-4-targeting peptide-drug conjugate (PDC), in patients with advanced or metastatic solid tumors: Results from dose-escalation study

EphA2 targeting PDC drug SC-102 received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA)

SC-101 granted ODD by FDA for the treatment of esophageal cancer

Conjustar biologics announced that SC-101 (Nectin-4-targeted PDC)  has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of esophageal cancer.